BIOCANCELL THERAPEUTICS INC.·4

Jul 6, 4:49 PM ET

Landsberg Moshe 4

4 · BIOCANCELL THERAPEUTICS INC. · Filed Jul 6, 2009

Insider Transaction Report

Form 4
Period: 2009-07-06
Landsberg Moshe
Vice President of Technology
Transactions
  • Purchase

    Common Stock, par value $0.01

    2009-07-06+7,1438,143 total
  • Award

    Employee Options

    2008-12-03+211,250260,000 total
    Exp: 2018-12-03Common Stock, par value $0.01 (211,250 underlying)
Footnotes (3)
  • [F1]The average purchase price was 2.80 NIS per share.
  • [F2]The exercise price is 1.27 NIS per share.
  • [F3]16,250 options shall be exercisable at the end of each calendar quarter, until September 30, 2012

Documents

1 file
  • 4
    a96976_ex.xmlPrimary